We and others have engineered oncolytic vaccinia viruses (VVs) expressing recombinant IL-2, IL-12, IL-15, IL-21, IL-23, and IL-36γ for improved efficacy and safety in multiple tumor models [64, 72–77]. The gene discussed is IL15; the disease is neoplasm.